Published in Vaccine on June 23, 2006
Low-Cost Molecular Cervical Cancer Screening Study | NCT01231945
Study of Pomalidomide in Anal Cancer Precursors (SPACE) | NCT03113942
Increasing HPV Immunization Rates: The Rural Adolescent Vaccine Enterprise (RAVE) | NCT03604393
Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst (2010) 3.88
Circumcision and human papillomavirus infection in men: a site-specific comparison. J Infect Dis (2008) 2.58
Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr (2008) 2.44
Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis. AIDS (2012) 2.15
Duration and clearance of anal human papillomavirus (HPV) infection among women: the Hawaii HPV cohort study. Clin Infect Dis (2009) 2.10
End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer (2011) 1.96
Transmission of human papillomavirus in heterosexual couples. Emerg Infect Dis (2008) 1.93
Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiol Biomarkers Prev (2009) 1.70
Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. J Clin Microbiol (2007) 1.66
Assessment of human papillomavirus in lung tumor tissue. J Natl Cancer Inst (2011) 1.59
The impact of infection on population health: results of the Ontario burden of infectious diseases study. PLoS One (2012) 1.58
High-risk HPV types and head and neck cancer. Int J Cancer (2014) 1.56
Acceptance of the HPV vaccine among women, parents, community leaders, and healthcare providers in Ohio Appalachia. Vaccine (2009) 1.53
Demographic, knowledge, attitudinal, and accessibility factors associated with uptake of cervical cancer screening among women in a rural district of Tanzania: three public policy implications. BMC Public Health (2012) 1.50
HPV - immune response to infection and vaccination. Infect Agent Cancer (2010) 1.48
The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer (2007) 1.45
Consistent condom use reduces the genital human papillomavirus burden among high-risk men: the HPV infection in men study. J Infect Dis (2013) 1.43
The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort. PLoS One (2016) 1.40
Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J Infect Dis (2009) 1.35
Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr (2010) 1.35
High risk HPV contamination of endocavity vaginal ultrasound probes: an underestimated route of nosocomial infection? PLoS One (2012) 1.35
Sexual orientation disparities in cancer-related risk behaviors of tobacco, alcohol, sexual behaviors, and diet and physical activity: pooled Youth Risk Behavior Surveys. Am J Public Health (2013) 1.26
Human papillomavirus type 16 genetic variants: phylogeny and classification based on E6 and LCR. J Virol (2012) 1.26
Prevalence and risk profile of cervical Human papillomavirus infection in Zhejiang Province, southeast China: a population-based study. Virol J (2010) 1.25
Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev (2010) 1.21
Human papillomaviruses: genetic basis of carcinogenicity. Public Health Genomics (2009) 1.18
Detection of genital HPV types in fingertip samples from newly sexually active female university students. Cancer Epidemiol Biomarkers Prev (2010) 1.18
Does framing human papillomavirus vaccine as preventing cancer in men increase vaccine acceptability? Cancer Epidemiol Biomarkers Prev (2010) 1.15
Expression of mir-21 and mir-143 in cervical specimens ranging from histologically normal through to invasive cervical cancer. PLoS One (2011) 1.13
Construction of a full transcription map of human papillomavirus type 18 during productive viral infection. J Virol (2011) 1.11
The role of cytidine deaminases on innate immune responses against human viral infections. Biomed Res Int (2013) 1.11
HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study. Br J Cancer (2011) 1.10
Discussing the diagnosis of HPV-OSCC: common questions and answers. Oral Oncol (2013) 1.09
The EVER proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections. Microbiol Mol Biol Rev (2009) 1.09
Validation of a low-cost human papillomavirus genotyping assay based on PGMY PCR and reverse blotting hybridization with reusable membranes. J Clin Microbiol (2011) 1.09
ADXS-HPV: a therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen. Hum Vaccin Immunother (2014) 1.08
Human papillomavirus (HPV) vaccine availability, recommendations, cost, and policies among health departments in seven Appalachian states. Vaccine (2009) 1.08
Epidemiology of, and behavioural risk factors for, sexually transmitted human papillomavirus infection in men and women in Britain. Sex Transm Infect (2012) 1.07
Epigenetic alterations in preneoplastic and neoplastic lesions of the cervix. Clin Epigenetics (2012) 1.06
Human Papillomaviruses and genital co-infections in gynaecological outpatients. BMC Infect Dis (2009) 1.06
Cervical human papillomavirus (HPV) infection in South African women: implications for HPV screening and vaccine strategies. J Clin Microbiol (2007) 1.05
A highly sensitive, multiplex broad-spectrum PCR-DNA-enzyme immunoassay and reverse hybridization assay for rapid detection and identification of Chlamydia trachomatis serovars. J Mol Diagn (2007) 1.05
Differences in the concentration and correlation of cervical immune markers among HPV positive and negative perimenopausal women. Cytokine (2011) 1.04
Mechanisms of cell entry by human papillomaviruses: an overview. Virol J (2010) 1.04
Comparison of natural histories of human papillomavirus detected by clinician- and self-sampling. Int J Cancer (2010) 1.04
Cutaneous squamous cell carcinoma and human papillomavirus: is there an association? Dermatol Surg (2012) 1.03
Age-standardized incidence and mortality rates of oral and pharyngeal cancer in Puerto Rico and among Non-Hispanics Whites, Non-Hispanic Blacks, and Hispanics in the USA. BMC Cancer (2009) 1.02
Sociodemographic predictors of HPV testing and vaccination acceptability: results from a population-representative sample of British women. J Med Screen (2008) 1.02
Serious Non-AIDS events: Immunopathogenesis and interventional strategies. AIDS Res Ther (2013) 1.01
Cervicovaginal self-sampling is a reliable method for determination of prevalence of human papillomavirus genotypes in women aged 20 to 30 years. J Clin Microbiol (2011) 1.00
Development and evaluation of a liquid bead microarray assay for genotyping genital human papillomaviruses. J Clin Microbiol (2009) 1.00
A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers. J Biol Chem (2010) 1.00
Perceived need of a parental decision aid for the HPV vaccine: content and format preferences. Health Promot Pract (2011) 0.97
Scaling up human papillomavirus vaccination: a conceptual framework of vaccine adherence. Sex Health (2010) 0.97
Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer. Biomed Res Int (2013) 0.97
Human papillomavirus community in healthy persons, defined by metagenomics analysis of human microbiome project shotgun sequencing data sets. J Virol (2014) 0.96
Prevalence and risk factors for oncogenic human papillomavirus infections in high-risk mid-adult women. Sex Transm Dis (2012) 0.96
Acquisition of high-risk human papillomavirus infection in a population-based cohort of Danish women. Sex Transm Dis (2009) 0.96
Membrane orientation of the human papillomavirus type 16 E5 oncoprotein. J Virol (2009) 0.96
Identification of unusual E6 and E7 proteins within avian papillomaviruses: cellular localization, biophysical characterization, and phylogenetic analysis. J Virol (2009) 0.95
Patterns of human papillomavirus DNA and antibody positivity in young males and females, suggesting a site-specific natural course of infection. PLoS One (2013) 0.95
Comparison of Seegene Anyplex II HPV28 with the PGMY-CHUV assay for human papillomavirus genotyping. J Clin Microbiol (2013) 0.95
Infection and cervical neoplasia: facts and fiction. Int J Clin Exp Pathol (2008) 0.94
Parental acceptance of HPV vaccine in Peru: a decision framework. PLoS One (2012) 0.94
The cancer cell map initiative: defining the hallmark networks of cancer. Mol Cell (2015) 0.94
Economic evaluation of three populational screening strategies for cervical cancer in the county of Valles Occidental: CRICERVA clinical trial. BMC Health Serv Res (2011) 0.93
Human papillomavirus 'reflex' testing as a screening method in cases of minor cytological abnormalities. Br J Cancer (2008) 0.93
Hybrid capture vs. PCR screening of cervical human papilloma virus infections. Cytological and histological associations in 1270 women. BMC Cancer (2010) 0.92
Human papillomavirus (HPV): college male's knowledge, perceived risk, sources of information, vaccine barriers and communication. J Mens Health (2011) 0.92
Mediation by peer violence victimization of sexual orientation disparities in cancer-related tobacco, alcohol, and sexual risk behaviors: pooled youth risk behavior surveys. Am J Public Health (2014) 0.91
Evaluation of transported dry and wet cervical exfoliated samples for detection of human papillomavirus infection. J Clin Microbiol (2010) 0.91
Ohio Appalachia public health department personnel: human papillomavirus (HPV) vaccine availability, and acceptance and concerns among parents of male and female adolescents. J Community Health (2012) 0.91
Population-based study on the prevalence of and risk factors for human papillomavirus infection in Qujing of Yunnan province, Southwest China. Virol J (2012) 0.90
Link between chronic inflammation and human papillomavirus-induced carcinogenesis (Review). Oncol Lett (2015) 0.90
Human papillomaviruses as therapeutic targets in human cancer. J Clin Oncol (2011) 0.90
Mortality in Danish patients with nonmelanoma skin cancer, 1978-2001. Br J Dermatol (2008) 0.90
A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer. Int J Public Health (2010) 0.90
Kinetics of DNA load predict HPV 16 viral clearance. J Clin Virol (2011) 0.89
Cervical cancer in India and HPV vaccination. Indian J Med Paediatr Oncol (2012) 0.89
Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention. Infect Agent Cancer (2008) 0.89
Impact of human papillomavirus-related genital diseases on quality of life and psychosocial wellbeing: results of an observational, health-related quality of life study in the UK. BMC Public Health (2013) 0.89
Human papillomavirus prevalence and type-specific relative contribution in invasive cervical cancer specimens from Italy. BMC Cancer (2010) 0.89
Viral load and short-term natural history of type-specific oncogenic human papillomavirus infections in a high-risk cohort of midadult women. Int J Cancer (2013) 0.89
Media coverage of cervical cancer and the HPV vaccine: implications for geographic health inequities. Health Expect (2011) 0.89
Integration of HIV and cervical cancer screening perceptions and preferences of communities in Uganda. BMC Womens Health (2015) 0.89
Cervical screening within HIV care: findings from an HIV-positive cohort in Ukraine. PLoS One (2012) 0.88
Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden. BMC Infect Dis (2011) 0.88
Intron definition and a branch site adenosine at nt 385 control RNA splicing of HPV16 E6*I and E7 expression. PLoS One (2012) 0.88
Parents' decision-making about the human papillomavirus vaccine for their daughters: II. Qualitative results. Hum Vaccin Immunother (2015) 0.88
Combined oral contraceptive use increases HPV persistence but not new HPV detection in a cohort of women from Thailand. J Infect Dis (2011) 0.87
Nuclear expression of Rac1 in cervical premalignant lesions and cervical cancer cells. BMC Cancer (2012) 0.87
E6^E7, a novel splice isoform protein of human papillomavirus 16, stabilizes viral E6 and E7 oncoproteins via HSP90 and GRP78. MBio (2015) 0.87
Circumcision and acquisition of human papillomavirus infection in young men. Sex Transm Dis (2011) 0.87
Small molecule inhibitors of the HPV16-E6 interaction with caspase 8. Bioorg Med Chem Lett (2012) 0.87
Estimated health and economic impact of quadrivalent HPV (types 6/11/16/18) vaccination in Brazil using a transmission dynamic model. BMC Infect Dis (2012) 0.87
Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children. J Infect Dis (2012) 0.87
Genital human papillomavirus infection among women in Bangladesh: findings from a population-based survey. PLoS One (2014) 0.86
HPV vaccine use among African American girls: qualitative formative research using a participatory social marketing approach. Gynecol Oncol (2014) 0.86
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol (2010) 9.86
Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer (2004) 6.99
Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis (2007) 6.86
Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst (2003) 6.28
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 5.57
Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis (2010) 4.42
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 3.98
Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol (2006) 3.13
Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial. Arch Intern Med (2012) 3.06
A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine (2012) 3.03
Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Ann Intern Med (2005) 2.82
Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst (2002) 2.75
Multiple ADH genes are associated with upper aerodigestive cancers. Nat Genet (2008) 2.53
An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine (2008) 2.48
Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis (2011) 2.19
Male circumcision and genital human papillomavirus: a systematic review and meta-analysis. Sex Transm Dis (2012) 2.16
Association between a 15q25 gene variant, smoking quantity and tobacco-related cancers among 17 000 individuals. Int J Epidemiol (2009) 1.97
Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog (2009) 1.92
E6 and E7 from beta HPV38 cooperate with ultraviolet light in the development of actinic keratosis-like lesions and squamous cell carcinoma in mice. PLoS Pathog (2011) 1.89
Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol (2009) 1.70
Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. Gynecol Oncol (2012) 1.70
TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol (2007) 1.70
A genome-wide association study of upper aerodigestive tract cancers conducted within the INHANCE consortium. PLoS Genet (2011) 1.68
Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine (2012) 1.68
Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer (2012) 1.66
Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res (2004) 1.53
Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes Chromosomes Cancer (2007) 1.50
Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer (2013) 1.42
Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer (2014) 1.40
Mouthwash use and cancer of the head and neck: a pooled analysis from the International Head and Neck Cancer Epidemiology Consortium. Eur J Cancer Prev (2016) 1.38
Virus-like particles as vaccines and vessels for the delivery of small molecules. Curr Opin Biotechnol (2004) 1.32
Human papillomavirus type 16 and TP53 mutation in oral cancer: matched analysis of the IARC multicenter study. Cancer Res (2004) 1.25
Eurogin Roadmap: comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix. Int J Cancer (2013) 1.25
Skin human papillomavirus type 38 alters p53 functions by accumulation of deltaNp73. EMBO Rep (2006) 1.24
Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol (2014) 1.23
The role of diet and nutrition in cervical carcinogenesis: a review of recent evidence. Int J Cancer (2005) 1.17
Resource consumption and costs of palliative care services in Spain: a multicenter prospective study. J Pain Symptom Manage (2006) 1.15
HPV and circumcision: a biased, inaccurate and misleading meta-analysis. J Infect (2007) 1.15
Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells. Virology (2004) 1.13
Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 European countries: the ARCAGE project. Cancer Res (2009) 1.12
Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Int J Cancer (2008) 1.12
Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol (2003) 1.12
Biological activity of probable/possible high-risk human papillomavirus types in cervical cancer. Int J Cancer (2012) 1.10
Diet and body mass, and oral and oropharyngeal squamous cell carcinomas: analysis from the IARC multinational case-control study. Int J Cancer (2006) 1.09
Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate. PLoS One (2012) 1.08
Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines. Vaccine (2008) 1.07
Genetic analysis identifies putative tumor suppressor sites at 2q35-q36.1 and 2q36.3-q37.1 involved in cervical cancer progression. Oncogene (2003) 1.07
Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1. J Virol (2006) 1.06
Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin. Vaccine (2009) 1.05
Diagnosing cervical cancer and high-grade precursors by HPV16 transcription patterns. Cancer Res (2009) 1.05
Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study. PLoS One (2013) 1.04
Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer (2007) 1.04
Prevalence and risk factors of sexually transmitted infections and cervical neoplasia in women from a rural area of southern Mozambique. Infect Dis Obstet Gynecol (2010) 1.03
HPV16 semiquantitative viral load and serologic biomarkers in oral and oropharyngeal squamous cell carcinomas. Int J Cancer (2005) 1.03
Comprehensive control of human papillomavirus infections and related diseases. Vaccine (2013) 1.02
Male circumcision, human papillomavirus and cervical cancer: from evidence to intervention. J Fam Plann Reprod Health Care (2009) 1.01
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. J Infect Dis (2013) 1.00
Skin hyperproliferation and susceptibility to chemical carcinogenesis in transgenic mice expressing E6 and E7 of human papillomavirus type 38. J Virol (2005) 0.99
Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques. Hum Gene Ther (2012) 0.98
Prospective investigation of body mass index, colorectal adenoma, and colorectal cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. J Clin Oncol (2013) 0.95
N2-ethyldeoxyguanosine as a potential biomarker for assessing effects of alcohol consumption on DNA. Cancer Epidemiol Biomarkers Prev (2008) 0.95
Body size and multiple myeloma mortality: a pooled analysis of 20 prospective studies. Br J Haematol (2014) 0.95
Smoking as a major risk factor for cervical cancer and pre-cancer: results from the EPIC cohort. Int J Cancer (2014) 0.94
p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer (2004) 0.94
Comparative analysis of transforming properties of E6 and E7 from different beta human papillomavirus types. J Virol (2011) 0.92
Human papillomavirus distribution in invasive cervical carcinoma in sub-Saharan Africa: could HIV explain the differences? Trop Med Int Health (2012) 0.92
Coverage and factors associated with cervical cancer screening: results from the AFRODITA study: a population-based survey in Spain. J Low Genit Tract Dis (2008) 0.91
Using prior information from the medical literature in GWAS of oral cancer identifies novel susceptibility variant on chromosome 4--the AdAPT method. PLoS One (2012) 0.90
Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. Virology (2002) 0.90
An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Vaccine (2006) 0.90
The role of human papillomavirus in head and neck cancer in Senegal. Infect Agent Cancer (2013) 0.89
Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity. J Virol (2009) 0.89
IkappaB kinase beta promotes cell survival by antagonizing p53 functions through DeltaNp73alpha phosphorylation and stabilization. Mol Cell Biol (2011) 0.89
Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity. Vaccine (2009) 0.89
A sex-specific association between a 15q25 variant and upper aerodigestive tract cancers. Cancer Epidemiol Biomarkers Prev (2011) 0.88
Endogenous sex steroids and risk of cervical carcinoma: results from the EPIC study. Cancer Epidemiol Biomarkers Prev (2011) 0.88
Dietary factors and in situ and invasive cervical cancer risk in the European prospective investigation into cancer and nutrition study. Int J Cancer (2010) 0.88
Enhanced papillomavirus-like particle production in insect cells. Virology (2009) 0.87
Efficiency of HPV 16 L1/E7 DNA immunization: influence of cellular localization and capsid assembly. Vaccine (2005) 0.87
Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs. Vaccine (2009) 0.87
Identification of B-cell epitopes on virus-like particles of cutaneous alpha-human papillomaviruses. J Virol (2009) 0.87
Prevalence, concordance and determinants of human papillomavirus infection among heterosexual partners in a rural region in central Mexico. BMC Infect Dis (2010) 0.87
Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants. Int J Cancer (2009) 0.86
Male circumcision and prevalence of genital human papillomavirus infection in men: a multinational study. BMC Infect Dis (2013) 0.85
Using HPV prevalence to predict cervical cancer incidence. Int J Cancer (2012) 0.85
Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors. Antivir Ther (2009) 0.84
Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention. Gynecol Oncol (2011) 0.84
High prevalence of human papillomavirus infection in the female population of Guatemala. Int J Cancer (2009) 0.84
Benign breast and gynecologic conditions, reproductive and hormonal factors, and risk of thyroid cancer. Cancer Prev Res (Phila) (2014) 0.84
Binding of human papilloma virus L1 virus-like particles to dendritic cells is mediated through heparan sulfates and induces immune activation. Immunobiology (2007) 0.84
T cell response to human papillomavirus 16 E7 in mice: comparison of Cr release assay, intracellular IFN-gamma production, ELISPOT and tetramer staining. Intervirology (2002) 0.84
Human papillomavirus type 38 E6 and E7 act as tumour promoters during chemically induced skin carcinogenesis. J Gen Virol (2012) 0.83
Modification of HPV 16 E7 genes: correlation between the level of protein expression and CTL response after immunization of C57BL/6 mice. Vaccine (2005) 0.83
NF-κ B-dependent upregulation of ICAM-1 by HPV16-E6/E7 facilitates NK cell/target cell interaction. Int J Cancer (2011) 0.83
Tumor prevention in HPV8 transgenic mice by HPV8-E6 DNA vaccination. Med Microbiol Immunol (2014) 0.83
Codon optimized expression of HPV 16 E6 renders target cells susceptible to E6-specific CTL recognition. Immunol Lett (2006) 0.83
Predictors of human papillomavirus infection in women undergoing routine cervical cancer screening in Spain: the CLEOPATRE study. BMC Infect Dis (2012) 0.83
Prophylactic DNA immunization against multiple papillomavirus types. Vaccine (2007) 0.83